Research Compounds

The foundational blend research stack: Body Protection Compound-157 paired with Thymosin Beta-4 in a single vial, pairing localized tissue-repair research with systemic healing research. The base every other blend on this page builds on.

The Wolverine Stack plus GHK-Cu in one vial — extending tissue-repair research into collagen synthesis, gene-expression, and dermal/follicular pathways alongside the same BPC-157 and TB-500 foundation.

The GLOW Stack plus KPV — a four-peptide blend extending the same tissue-repair and collagen research into anti-inflammatory and gut-lining pathways in a single reconstitution.

A co-formulated metabolic research blend pairing retatrutide — an investigational triple GIP/GLP-1/glucagon receptor agonist — with cagrilintide, a long-acting amylin analog, in a single vial (12.5 mg / 2.5 mg). Studied for overlapping incretin and amylin signaling pathways. Both compounds are investigational and unapproved; provided strictly as a chemical reagent for laboratory research use only.

A co-formulated metabolic research blend pairing cagrilintide — a long-acting amylin analog — with semaglutide, a GLP-1 receptor agonist, in a single vial. The dual amylin-plus-GLP-1 approach was studied in Novo Nordisk's Phase 3 REDEFINE program, where the combination produced greater weight reduction than either component alone. Semaglutide is FDA-approved only as a specific finished drug; the bulk peptide and this combination are unapproved and provided strictly as a chemical reagent for laboratory research use only.